SCHEMBL9770647

SCHEMBL9770647

O=C1c2ccccc2C(=O)N1COc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.66
MAPT P10636 1/20 0.66
SMN1; SMN2 Q16637 1/20 0.66
MGAM O43451 2/20 0.55
GAA P10253 2/20 0.55
SI P14410 2/20 0.55
MGAM2 Q2M2H8 2/20 0.55
LMNA P02545 1/20 0.54
PKM P14618 1/20 0.54
HPGD P15428 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
NPC1 O15118 1/20 0.51
ALDH1A1 P00352 2/20 0.51
RECQL P46063 1/20 0.51
CA12 O43570 1/20 0.50
CA9 Q16790 1/20 0.50
GRM5 P41594 1/20 0.49
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
RPS6KA2 Q15349 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8614129 0.85 RAB9A (0.50) RAB9AMAPTSMN1; SMN2MGAMGAA
SCHEMBL9770552 0.85 RAB9A (0.71) RAB9ASMN1; SMN2MGAMGAASI
Hydrochloric Acid SCHEMBL8616864 0.84 MGAM (0.49) RAB9AMAPTSMN1; SMN2MGAMGAA
SCHEMBL8616895 0.81 HTT (0.53) RAB9AMAPTSMN1; SMN2MGAMGAA
SCHEMBL1578469 0.81 RAB9A (0.83) RAB9AMAPTSMN1; SMN2LMNAPKM
SCHEMBL4158450 0.80 CES1 (0.61) MAPTLMNAPKMALDH1A1KMT2A
SCHEMBL9770478 0.80 SCN2A (0.54) RAB9AMAPTMGAMGAASI
SCHEMBL7299163 0.79 RAB9A (1.00) RAB9AMAPTSMN1; SMN2LMNAPKM
SCHEMBL8764222 0.79 MGLL (0.52) RAB9AMAPTSMN1; SMN2
SCHEMBL1626840 0.79 CA12 (0.52) RAB9AMAPTSMN1; SMN2GAAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105283-A1 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS GILEAD PALO ALTO, INC. 2009-04-23 US disclosed
US-20080255161-A1 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS GILEAD PALO ALTO, INC. 2008-10-16 US disclosed
US-5001115-A Prodrugs of biologically active hydroxyaromatic compounds UNIVERSITY OF FLORIDA (US) 1991-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255161-A1 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS SCD, SCD5, ECHS1 RAB9A 2039/4885MAPT 4221/4885SMN1; SMN2 3593/4885
US-20090105283-A1 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS SCD, SCD5, ECHS1 RAB9A 2039/4885MAPT 4221/4885SMN1; SMN2 3593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.